Skip to content

Clinical Prescribing System Resources for transitioning patients from Levemir® (insulin detemir)

Logo

This site and associated resources have been funded by Novo Nordisk UK and developed in conjunction with Oberoi Consulting. They are intended for Healthcare Professionals (HCPs) and Other Relevant Decision Makers (ORDMs) who have population level decision making capability for their Healthcare Organisation. Clinical discretion should be exercised by the HCP to determine the best management plan for their patients.

REGISTRATION

Please complete the fields below to register to access the clinical prescribing system resources for transitioning patients from Levemir®.

Once your registration has been validated by Oberoi, you will receive an automated email confirming that your account has been activated.

I understand that Novo Nordisk UK have developed and funded this clinical support programme as part of a package deal for patients prescribed Levemir®. The aim of this initiative is to support the NHS in identifying patients using Levemir®, to assist in their transition to an alternative treatment ahead of its planned discontinuation in the UK in December 2026.​

To abide by the ABPI Code of Practice, Novo Nordisk UK is required to make public certain details of payments and transfers of value or in kind (“ToV requirements”) including those made to healthcare organisations whose primary practice, principal professional address, or place of incorporation is in Europe or the UK. To comply with the ToV requirements Novo Nordisk UK will disclose transfers of value as required by law, relevant authorities and/or industry codes of practice. 

For the purposes of the ToV requirements, Novo Nordisk UK will have an obligation to disclose the value of the clinical prescribing system resources package deal as part of ToV requirements. For the purposes of such disclosure, the following value will be assigned to the package deal: £375.30

In order to enable Novo Nordisk UK to comply with this obligation, Oberoi Consulting will share required information only with Novo Nordisk. The only information that shall be shared with Novo Nordisk UK will be the name of the healthcare organisation that you are registering on behalf of. 
Your email will only be used to administer access to this Site

Personal Details

Oberoi Consulting Ltd (“Oberoi”) will collect and use your personal data that you share with us, such as your name, contact details and professional role, for the purpose of managing and administering your account as Data Controller jointly with Novo Nordisk Ltd (“Novo Nordisk UK”).

However, please note that Novo Nordisk UK will not have access to your personal data and we will not share your personal data with Novo Nordisk or any third party.​

We will store your personal data for as long as the project remains active, unless a longer retention period is needed or allowed by law. For more information about how Oberoi process your data please refer to the Oberoi Privacy and Cookie Policy here.

As an authorised decision maker on behalf of the HCO, please enter your contact details and role below. These details will be used to validate your registration.

Required for receiving your login details
Adverse Event Reporting

Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse Events should also be reported to Novo Nordisk UK (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes.

Job code: UK25LV00018 |

Date of Prep: Nov 2025